Trends in Risk-Reducing Mastectomy and Risk-Reducing SalpingoOophorectomy in Korean Carriers of the BRCA1/2 Mutation
- Author:
Sung Mi JUNG
1
;
Jai Min RYU
;
Hyung Seok PARK
;
Ji Soo PARK
;
Eunyoung KANG
;
Seeyoun LEE
;
Han-Byoel LEE
;
Hyun Jo YOUN
;
Tae-Kyung YOO
;
Jisun KIM
;
Jeong Eon LEE
;
Sang Ah HAN
;
Dongwon KIM
;
Sung-Won KIM
;
Author Information
- Publication Type:Original Article
- From:Journal of Breast Cancer 2020;23(6):647-655
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:BRCA1/2 mutations are associated with risks of breast and ovarian cancer. In Korea, incidences of BRCA1/2 genetic testing and risk-reducing surgery (RRS) have increased with insurance coverage and the Angelina Jolie effect. The aim of this study was to identify trends in RRS performed in Korean women with the BRCA1/2 mutation.
Methods:We retrospectively reviewed the medical records of BRCA1/2 mutation carriers with (affected carriers) and without (unaffected carriers) breast cancer until August 2018 from 25 Korean Hereditary Breast Cancer (KOHBRA)-affiliated hospitals.
Results:The numbers of contralateral risk-reducing mastectomy (RRM) and risk-reducing bilateral salpingo-oophorectomy (RRBSO) in affected carriers have increased 5.8- and 3.6-fold, respectively, since 2013. The numbers of RRBSO in unaffected carriers has increased 8-fold since 2013. The number of institutions that perform RRS has increased gradually. The number of hospitals that perform contralateral RRM on affected carriers increased from 3 in 2012 to 11 in 2018, and that of those that perform RRBSO increased from 7 to 17. The number of hospitals that perform bilateral RRM on unaffected carriers increased from 1 in 2012 to 2 in 2018, and that of those that perform RRBSO increased from 1 to 8. However, the hospitals showed differences in the rates of RRM or RRBSO performed.
Conclusion:The incidence of RRS increased each year throughout the study period. However, in Korea, the rate of RRS procedures depended on the hospital.
